Categories AlphaGraphs, Earnings, Energy
Earnings: Schlumberger (SLB) Q2 profit rises as revenues grow 20%
Energy giant Schlumberger Limited (NYSE: SLB) on Friday reported higher earnings and revenues for the second quarter of 2022, with all four operating segments registering double-digit growth.
At $6.8 billion, total revenues were up 20% year-over-year. The core Well Construction and Production Systems segments grew 27% and 13% respectively.
The strong top-line growth translated into a 67% increase in adjusted earnings to $0.50 per share. Unadjusted profit more than doubled to $959 million or $0.67 per share. The management expects full-year 2022 capital investment to grow 18% to $2 billion.
Check this space to read management/analysts’ comments on Schlumberger’s Q2 2022 earnings
“The strength of our second-quarter outperformance highlights a firmly established growth inflection and our ability to comprehensively participate in drilling and completion activity growth globally. The multi-year upcycle continues to gain momentum with upstream activity and service pricing steadily increasing both internationally and in North America, resulting in a strengthened outlook for Schlumberger,” said Schlumberger’s CEO Olivier Le Peuch.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent